Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Relay TherapeuticsRLAY +1.59%53 Cash Ratio is 17.93 as of Jun. 2026, which is 14% below its 10-year median of 20.87. GuruFocus rates RLAY with a GF Score™ of 53/100 and a GF Value™ of $3.80 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,382 Biotechnology companies, Relay Therapeutics ranks better than 91.1% on this metric.
Relay Therapeutics has a Cash Ratio of 17.93. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Relay Therapeutics's Cash Ratio or its related term are showing as below:
RLAY'
s Cash Ratio Range Over the Past 10 Years
Min: 12.18 Med: 20.87 Max: 61.4
Current: 17.93
During the past 8 years, Relay Therapeutics's highest Cash Ratio was 61.40. The lowest was 12.18. And the median was 20.87.
RLAY's Cash Ratio is ranked better than 91.1% of 1382
companies
in the Biotechnology industry
Industry Median: 2.97
vs RLAY: 17.93
Relay Therapeutics (NAS:RLAY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Relay Therapeutics Cash Ratio Related Terms
Relay Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Relay Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Relay Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (RLAY) has a Cash Ratio of 17.93 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Relay Therapeutics and its competitors. This is 14% below median its historical median of 20.87. Over the past decade, Relay Therapeutics' Cash Ratio has ranged from 12.18 to 61.40. According to the industry distribution chart, Relay Therapeutics ranks #123 out of 1382 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Relay Therapeutics' Cash Ratio too high?
Relay Therapeutics' current Cash Ratio of 17.93 is 14% below median its 10-year median of 20.87. Over the past 10 years, this metric has ranged from a low of 12.18 to a high of 61.40. The Biotechnology industry median Cash Ratio is 2.97. Relay Therapeutics' value of 17.93 is 503.7% above this industry median. Based on the distribution chart, Relay Therapeutics ranks #123 out of 1382 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Relay Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Cash Ratio compare to CELC and VKTX?
According to the Biotechnology industry distribution chart, Relay Therapeutics ranks #123 out of 1382 companies for Cash Ratio. This places Relay Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.97. Relay Therapeutics' value of 17.93 is 503.7% above this benchmark. Historically, Relay Therapeutics' own Cash Ratio has ranged from 12.18 to 61.40 over the past decade. While the company's 10-year median is 20.87 vs. the industry median of 2.97, Relay Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relay Therapeutics's current Cash Ratio of 17.93 is 503.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Relay Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relay Therapeutics's current Cash Ratio is 17.93, which is 14% below median its own 10-year median of 20.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.40 — trading 436.8% above its estimated fair value. The current Cash Ratio is 17.93, which is 14% below median its 10-year median of 20.87 and 503.7% above the Biotechnology industry median of 2.97. Relay Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Cash Ratio is 17.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relay Therapeutics (RLAY) Overvalued in 2026?
Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued.
The current stock price of $20.40 is trading 436.8% above its estimated GF Value™ of $3.80.
GuruFocus considers Relay Therapeutics to be Significantly Overvalued.
Key valuation signals for RLAY:
Cash Ratio: 17.93 (14% below median its 10-year median of 20.87)
GF Value™: $3.80 vs. price of $20.40 (436.8% above fair value)
Industry Position: 503.7% above the Biotechnology median (#123 of 1382)
No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
53GF Score
Get the complete analysis for RLAY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLAY has been successfully added to your 
